Welcome to our dedicated page for Lumexa Imaging Holdings SEC filings (Ticker: LMRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Lumexa Imaging Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Lumexa Imaging Holdings's regulatory disclosures and financial reporting.
BROWN ADVISORY INC, together with subsidiaries Brown Advisory LLC, Brown Investment Advisory & Trust Co, and Signature Financial Management, Inc., reports beneficial ownership of common stock of Lumexa Imaging Holdings, Inc.
The group reports beneficial ownership of 5,842,935 shares of Lumexa common stock, representing 6.08% of the class. Reported voting power is primarily sole, including 5,487,188 shares for Brown Advisory Inc, 75,048 for Brown Investment Advisory & Trust Co, 3,590 for Signature Financial Management, Inc., and 5,408,550 for Brown Advisory LLC. Dispositive power is reported as shared, including 5,837,497 shares for Brown Advisory Inc and 5,763,534 for Brown Advisory LLC.
The securities are beneficially owned by investment companies and other managed accounts of direct or indirect subsidiaries of Brown Advisory Inc, which may be deemed beneficial owners under investment advisory contracts providing voting and/or investment power.
Lumexa Imaging Holdings, Inc. reported improved results for the three and six months ended June 30, 2026. Total revenues were $264.2 million in the quarter and $516.7 million year-to-date, modestly higher than the prior-year periods.
The company generated quarterly net income of $2.7 million and year-to-date net income of $4.5 million, compared with net losses a year earlier. Operating income declined year-over-year as cost of operations, general and administrative expenses, and stock-based compensation increased, but this was more than offset at the bottom line by sharply lower interest expense and strong equity earnings from unconsolidated affiliates.
Lumexa produced $35.7 million of cash from operating activities in the first half of 2026 versus an outflow in 2025, ending the period with $69.7 million in cash and cash equivalents. The balance sheet shows $835.4 million of long-term debt (net of issuance costs), reflecting a leveraged capital structure, while total equity increased to $615.1 million
Lumexa Imaging Holdings, Inc. reported second quarter 2026 results and updated its full year 2026 outlook. Total revenues were $264.2 million, up from $251.4 million a year earlier, driven by higher net patient service revenue and management fee and other revenue.
The company generated net income of $2.7 million, compared with a net loss of $7.2 million in Q2 2025. Adjusted EBITDA was $56.4 million, essentially in line with $56.3 million a year ago, while adjusted diluted EPS rose to $0.20 from $0.08. Outpatient volumes increased, with consolidated total procedures up to 617,722 and advanced procedures rising faster than overall volumes.
For the first six months of 2026, Lumexa Imaging posted net income of $4.5 million versus a loss of $14.9 million in the prior-year period and generated $35.7 million of cash from operating activities, compared with cash used of $11.9 million a year earlier. At June 30, 2026, total assets were $1.81 billion, total liabilities $1.19 billion, and equity $615.1 million.
Lumexa Imaging Holdings, Inc. has amended its main debt facilities through an updated credit agreement for its subsidiaries. The new structure includes a secured term loan of approximately $823 million, called the Replacement Term Loan, and a secured revolving credit facility of $250 million.
Both facilities bear interest at the borrowers’ option at SOFR plus 2.50% or the Prime Rate plus 1.50%. The Replacement Term Loan matures in December 2032, while the Amended Revolving Credit Facility matures in December 2030, extending the company’s debt maturity profile.
The agreement imposes restrictive covenants on subsidiary actions such as incurring additional debt and paying dividends, and introduces a financial covenant if revolving exposure exceeds 40% of the revolver’s principal. In that case, Lumexa’s consolidated net leverage ratio must not exceed 7.50 to 1, with standard lender remedies available after an event of default.
Mittl Robert Louis Jr. reported acquisition or exercise transactions in this Form 4 filing.
Lumexa Imaging Holdings, Inc. director Robert Louis Mittl Jr. received an equity award in the form of restricted stock units. He was granted 19,358 RSUs, each representing the right to receive one share of Lumexa common stock.
The RSUs vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of Lumexa’s stockholders, as long as he continues serving the company. Following this award, he holds 19,358 shares/units directly, reflecting compensation rather than an open-market share purchase or sale.
Lungren Matthew reported acquisition or exercise transactions in this Form 4 filing.
Lumexa Imaging Holdings, Inc. reported that director Matthew Lungren received a grant of 19,358 restricted stock units (RSUs) of common stock. The award was recorded at a price of $0.00 per share because it is a stock-based compensation grant, not an open-market purchase.
The RSUs represent the right to receive an equal number of common shares and will vest on the earlier of one year from the grant date or the next annual stockholder meeting, as long as Lungren continues serving the company. After this grant, he directly holds 19,358 common shares tied to this award.
Karlin Bridget E reported acquisition or exercise transactions in this Form 4 filing.
Lumexa Imaging Holdings, Inc. director Bridget E. Karlin received an equity grant of 19,358 restricted stock units (RSUs), each representing one share of common stock. The award was granted at no cash cost per unit and is a form of stock-based compensation rather than an open-market purchase.
The RSUs will vest on the earlier of one year from the grant date or the next annual stockholder meeting, provided she continues serving the company. Following this grant, her reported direct holding related to this award is 19,358 shares/RSUs, aligning her compensation more closely with shareholder value.
Lumexa Imaging Holdings, Inc. director Joseph Molly reported an equity compensation grant. He acquired 19,358 shares of common stock at a price of $0.00 per share as a grant or award, increasing his direct holdings to 46,385 shares.
The award is structured as restricted stock units, each representing the right to receive one share of common stock. These RSUs vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, as long as Molly continues to serve the company.
EISENBERG GLENN A reported acquisition or exercise transactions in this Form 4 filing.
Lumexa Imaging Holdings, Inc. director Glenn A. Eisenberg received an equity compensation grant of 19,358 restricted stock units (RSUs) of common stock on June 10, 2026. Each RSU represents the right to receive one share of common stock if vesting conditions are met.
The RSUs will vest on the earlier of the one-year anniversary of the grant date and the next annual meeting of Lumexa Imaging’s stockholders, subject to Eisenberg’s continued service with the company. Following this award, he holds 19,358 shares/RSUs directly according to the filing.
Cooper Henry Lee reported acquisition or exercise transactions in this Form 4 filing.
Lumexa Imaging Holdings director Cooper Henry Lee reported a compensation-related equity grant and his indirect holdings. He received 19,358 shares of common stock as restricted stock units at $0.00 per share, which vest on the earlier of one year from grant or the next annual stockholder meeting, subject to continued service. Following this grant, he holds 19,358 shares directly and 30,000 shares indirectly through the Cooper Family Trust, where he and his spouse are co-trustees, with beneficial ownership of the trust shares disclaimed except for his pecuniary interest.